ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BARC Barclays Plc

202.35
1.35 (0.67%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Barclays Plc LSE:BARC London Ordinary Share GB0031348658 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.35 0.67% 202.35 202.10 202.20 203.40 199.58 202.50 47,820,183 16:35:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Commercial Banks, Nec 25.38B 5.26B 0.3470 5.83 30.63B

Barclays Appoints David Parrot as Head of US West Coast Biotech Banking

10/12/2018 3:15pm

Business Wire


Barclays (LSE:BARC)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Barclays Charts.

Barclays announces the appointment of David Parrot as Managing Director and Head of Barclays’ US West Coast Biotech Banking franchise. Mr. Parrot will be based in Menlo Park, California, and will report to Rick Landgarten, Global Head of Healthcare & Real Estate Groups at Barclays.

Mr. Parrot joins Barclays with close to 30 years of experience in banking, most recently as Head of Life Science Investment Banking at SunTrust Robinson Humphrey. Prior to joining SunTrust in 2015, Mr. Parrot was Co-Head of Life Science Investment Banking at BMO Capital Markets. Mr. Parrot joined BMO Capital Markets in 2010 after spending one year at Montgomery & Co., prior to which he was a founding member of the Life Sciences Investment Banking Group at Piper Jaffray & Co., joining in 1998.

“As Biotech continues to see rapid and marked evolution, we are excited about the great value David’s experience and abilities will bring to our clients,” said Rick Landgarten, Global Head of Healthcare & Real Estate Groups. “David’s hire is further evidence of our significant investment of resources in our strong Biotech franchise, and his deep and longstanding industry relationships and extensive transactional expertise make him a superb addition to our team.”

“Barclays is committed to investing in top talent to enable us to continue to drive mind and market share with our clients, and this is perfectly demonstrated in David’s hire,” added John Miller, Global Head of Banking Coverage. “The Biotech space represents a critical opportunity-set for our investment banking business, and David’s addition to the team will ensure that we continue to build on the strong momentum in our broader Healthcare franchise.”

Mr. Parrot is expected to start in early March 2019.

Barclays is a transatlantic consumer and wholesale bank offering products and services across personal, corporate and investment banking, credit cards and wealth management, with a strong presence in our two home markets of the UK and the US. With over 325 years of history and expertise in banking, Barclays operates in over 40 countries and employs approximately 80,000 people. Barclays moves, lends, invests and protects money for customers and clients worldwide. For further information about Barclays, please visit our website home.barclays

Andrew Smith+1 212 412 7521andrew.x.smith@barclays.com

1 Year Barclays Chart

1 Year Barclays Chart

1 Month Barclays Chart

1 Month Barclays Chart

Your Recent History

Delayed Upgrade Clock